Goldman Sachs’s Royalty Pharma RPRX Stock Holding History

Goldman Sachs’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.2M	Hold	25,000	–	–	﹤0.01%	4965
2025 Q4	$966K	Buy	+25,000	New	+$953K	﹤0.01%	5169
2022 Q2	–	Sell	-100,000	Closed	-$3.9M	–	6670
2022 Q1	$3.9M	Buy	+100,000	New	+$3.93M	﹤0.01%	3588
2021 Q3	–	Sell	-68,000	Closed	-$2.79M	–	6474
2021 Q2	$2.79M	Buy	+68,000	New	+$2.89M	﹤0.01%	3908

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs's RPRX Position: Q1 2026 in Review

Goldman Sachs increased its Royalty Pharma (RPRX) stake by 63% in Q1 2026, buying an estimated $42.6M and bringing the position to 2,522,546 shares worth $121M. The position accounts for 0.01% of the portfolio, ranked #919.

Goldman Sachs first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Goldman Sachs held 2,522,546 shares of Royalty Pharma worth $121M as of Q1 2026.
Goldman Sachs bought 971,646 Royalty Pharma shares in Q1 2026, an estimated $42.6M.
Royalty Pharma made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #919 holding.
Goldman Sachs first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.